Cabaletta Bio, Inc.CABA
What Cabaletta Bio, Inc. does.
We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA ® , or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach. CARTA refers to Chimeric Antigen Receptor T cells for Autoimmunity and is designed to potentially reset the immune system. Based on clinical data reported to date, we believe our CABA ® platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized.
Resecabtagene autoleucel, or rese-cel (formerly referred to as CABA-201), is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a broad range of autoimmune diseases and our lead product candidate within the CARTA strategy. Rese-cel is designed to achieve transient and deep depletion of all B cells following a single, weight-based infusion of T cells that are engineered to express an antibody fragment that recognizes a B cell receptor expressed on the surface of all B cells. The construct is designed to allow for the deep elimination of all B cells, including all B cells that contribute to disease, with subsequent repopulation by healthy transitional, naïve B cells. This approach has demonstrated the potential to reset the immune system and result in meaningful clinical responses without chronic therapy requirements in patients. The efficacy and safety of rese-cel was recently reviewed along with all other commercial and academic constructs in development in a February 2026 Nature Biotechnology publication.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$33.3M | -$46.3M | -$53.0M | -$67.7M | -$115.9M | -$167.9M |
| Free cash flow | -$27.4M | -$35.3M | -$48.8M | -$54.2M | -$90.4M | -$132.3M |
More on CABA.
- Cabaletta Bio, Inc. summary
- Cabaletta Bio, Inc. financial statements
- Cabaletta Bio, Inc. key metrics
- Cabaletta Bio, Inc. health scores and style box
- Cabaletta Bio, Inc. earnings
- Cabaletta Bio, Inc. dividends
- Cabaletta Bio, Inc. valuation
- Cabaletta Bio, Inc. ownership and insiders
- Cabaletta Bio, Inc. peers
Figures from Cabaletta Bio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.